Healthy Male Individuals Possess Higher Plasma HER-2 Level Than Females

Overview

Journal Cell J

Specialty Cell Biology

Date 2023 Jan 21

PMID 36680486

Authors

Sepand Tehrani Fateh

Abbas Behgozin

Farshid Yekani

Lobat Geranpayeh

Asieh Olfatbakhsh

Shiva Moghaddam

Ramin Sarami Forroshani

Amir Salehi-Najafabadi

Faezeh Shekari

Affiliations

Soon will be listed here.

Abstract

Considering HER2 as one of the well-known biomarkers in the cancer field, and published articles regarding serum levels of HER2, in this paper we tried to highlight the issue that most studies don't stratify the HER-2 concentration of individuals in terms of gender. In this brief survey, healthy individuals with no prior non-communicable diseases were categorized as males (n=34) and females (n=43), and all samples were evaluated for plasma HER-2 levels at once. Surprisingly, the plasma level of HER-2 of healthy male individuals (mean= 2.28 ± 0.21 ng/mL) was significantly (P<0.0001) higher than the plasma level of HER-2 of healthy females (mean: 0.06 ± 0.09 ng/mL), with no overlap. Therefore, we suggest that more studies are required to re-check the cutoff values for HER-2 plasma levels based on gender since the clinical implications of a unique HER-2 cutoff for both genders may be seriously concerning.

Citing Articles

Investigating the Co-Expression Rate of HER2 and HER3 Biomarkers in Cancer Patients: A Systematic Review and Meta-Analysis.

Makoui R, Fekri S, Ansari N, Makoui M Asian Pac J Cancer Prev. 2024; 25(9):2979-2990.

PMID: 39342574 PMC: 11700328. DOI: 10.31557/APJCP.2024.25.9.2979.

References

Lee S, Lee J, Yu J, Ko B, Kim H, Son B . Preoperative serum HER2 extracellular domain levels in primary invasive breast cancer. BMC Cancer. 2014; 14:929. PMC: 4295268. DOI: 10.1186/1471-2407-14-929. View

Fernandez-Real J, Menendez J, Fruhbeck G, Moreno-Navarrete J, Vazquez-Martin A, Ricart W . Serum HER-2 concentration is associated with insulin resistance and decreases after weight loss. Nutr Metab (Lond). 2010; 7:14. PMC: 2841191. DOI: 10.1186/1743-7075-7-14. View

Corti C, Giachetti P, Eggermont A, Delaloge S, Curigliano G . Therapeutic vaccines for breast cancer: Has the time finally come?. Eur J Cancer. 2021; 160:150-174. PMC: 8608270. DOI: 10.1016/j.ejca.2021.10.027. View

Darlix A, Lamy P, Lopez-Crapez E, Braccini A, Firmin N, Romieu G . Serum HER2 extra-cellular domain, S100ß and CA 15-3 levels are independent prognostic factors in metastatic breast cancer patients. BMC Cancer. 2016; 16:428. PMC: 4937557. DOI: 10.1186/s12885-016-2448-1. View

Al-Saad S, Al-Shibli K, Donnem T, Andersen S, Bremnes R, Busund L . Clinical significance of epidermal growth factor receptors in non-small cell lung cancer and a prognostic role for HER2 gene copy number in female patients. J Thorac Oncol. 2010; 5(10):1536-43. DOI: 10.1097/JTO.0b013e3181ea510a. View

Eppenberger-Castori S, Klingbiel D, Ruhstaller T, Dietrich D, Rufle D, Rothgiesser K . Plasma HER2ECD a promising test for patient prognosis and prediction of response in HER2 positive breast cancer: results of a randomized study - SAKK 22/99. BMC Cancer. 2020; 20(1):114. PMC: 7014942. DOI: 10.1186/s12885-020-6594-0. View

Miller S, Hung M . Regulation of her2/neu gene-expression (review). Oncol Rep. 2011; 2(4):497-503. DOI: 10.3892/or.2.4.497. View

Venetis K, Crimini E, Sajjadi E, Corti C, Guerini-Rocco E, Viale G . HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the Spectrum of HER2 Positivity in Breast Cancer. Front Mol Biosci. 2022; 9:834651. PMC: 8965450. DOI: 10.3389/fmolb.2022.834651. View

Wang H, Liao X, Zhang J . Clinicopathological factors associated with HER2-positive gastric cancer: A meta-analysis. Medicine (Baltimore). 2017; 96(44):e8437. PMC: 5682803. DOI: 10.1097/MD.0000000000008437. View

10.

Phipps A, Malone K, Porter P, Daling J, Li C . Reproductive and hormonal risk factors for postmenopausal luminal, HER-2-overexpressing, and triple-negative breast cancer. Cancer. 2008; 113(7):1521-6. PMC: 2587413. DOI: 10.1002/cncr.23786. View

11.

Bagli L, Dittadi R, Zancan M, Panzini I, Monti F, Ravaioli A . HER-2/neu serum levels and menopausal status. Int J Biol Markers. 2001; 16(1):69-70. DOI: 10.1177/172460080101600110. View

12.

Di Gioia D, Dresse M, Mayr D, Nagel D, Heinemann V, Kahlert S . Serum HER2 supports HER2-testing in tissue at the time of primary diagnosis of breast cancer. Clin Chim Acta. 2014; 430:86-91. DOI: 10.1016/j.cca.2013.12.036. View

13.

Shamshirian A, Aref A, Yip G, Warkiani M, Heydari K, Razavi Bazaz S . Diagnostic value of serum HER2 levels in breast cancer: a systematic review and meta-analysis. BMC Cancer. 2020; 20(1):1049. PMC: 7603697. DOI: 10.1186/s12885-020-07545-2. View

14.

Sui F, Sun W, Su X, Chen P, Hou P, Shi B . Gender-related differences in the association between concomitant amplification of AIB1 and HER2 and clinical outcomes in glioma patients. Pathol Res Pract. 2018; 214(9):1253-1259. DOI: 10.1016/j.prp.2018.06.013. View

15.

Spath F, Andersson U, Dahlin A, Langseth H, Hovig E, Johannesen T . Pre-diagnostic serum levels of EGFR and ErbB2 and genetic glioma risk variants: a nested case-control study. Tumour Biol. 2016; 37(8):11065-72. PMC: 4999462. DOI: 10.1007/s13277-015-4742-y. View

16.

Atallah N, Toss M, Green A, Mongan N, Ball G, Rakha E . Refining the definition of HER2-low class in invasive breast cancer. Histopathology. 2022; 81(6):770-785. PMC: 9826019. DOI: 10.1111/his.14780. View

17.

Ferraro E, Drago J, Modi S . Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions. Breast Cancer Res. 2021; 23(1):84. PMC: 8356386. DOI: 10.1186/s13058-021-01459-y. View

18.

Ajayi O, Charles-Davies M, Anetor J, Ademola A . Pituitary, Gonadal, Thyroid Hormones and Endocrine Disruptors in Pre and Postmenopausal Nigerian Women with ER-, PR- and HER-2-Positive and Negative Breast Cancers. Med Sci (Basel). 2018; 6(2). PMC: 6024786. DOI: 10.3390/medsci6020037. View

19.

Read L, Keith Jr D, Slamon D, Katzenellenbogen B . Hormonal modulation of HER-2/neu protooncogene messenger ribonucleic acid and p185 protein expression in human breast cancer cell lines. Cancer Res. 1990; 50(13):3947-51. View